Technology ID

Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets

Lead Inventor
Desai, Sanjay (NIAID)
Therapeutic Areas
Infectious Disease
Development Status
  • Early-stage
  • Pre-clinical
  • In vitro data available
Lead IC
There are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that the PSAC inhibitors are able to inhibit growth of malaria parasites, have high specificity, and low toxicity. Portions of the PSAC protein are found on the outer surface of infected host erythrocytes and the protein was recently shown to be encoded by the clag3 gene. This discovery opens the possibility of developing the PSAC protein as a potential vaccine candidate against malaria.
Commercial Applications
  • Antimalarial drugs
  • Malaria vaccine
Competitive Advantages
  • Novel target against malaria
  • Small molecule inhibitors of PSAC inhibit malarial parasite growth, have low toxicity, and high specificity
  • PSAC protein is exposed on the surface of the infected host erythrocytes, making it an attractive vaccine candidate
Licensing Contact:
Tung, Peter
Phone: 240-669-5483